You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Litigation Details for United Therapeutics Corporation v. Liquidia Technologies, Inc. (Fed. Cir. 2023)


✉ Email this page to a colleague

« Back to Dashboard


United Therapeutics Corporation v. Liquidia Technologies, Inc. (Fed. Cir. 2023)

Docket ⤷  Sign Up Date Filed 2023-04-26
Court Court of Appeals for the Federal Circuit Date Terminated 2023-12-20
Cause Assigned To
Jury Demand Referred To
Parties UNITED THERAPEUTICS CORPORATION
Patents 6,521,212; 6,702,997; 6,756,033; 6,765,117; 7,417,070; 7,544,713; 8,497,393; 9,339,507; 9,358,240; 9,593,066; 9,604,901
Attorneys William Covington Jackson, Esq., Attorney
Firms McDermott Will & Emery
Link to Docket External link to docket
Small Molecule Drugs cited in United Therapeutics Corporation v. Liquidia Technologies, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , and ⤷  Sign Up .

Details for United Therapeutics Corporation v. Liquidia Technologies, Inc. (Fed. Cir. 2023)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 External link to document
2023-04-26 1 Voswinckel JESC, Voswinckel JAHA, and U.S. Patent No. 6,521,212 B1 (Ex. 1006); (…Pub. L. No. 112–29, 125 Stat. 284 (2011). 3 US 6,521,212 B1, issued Feb. 18, 2003 (Ex. 1006) (alleged to… Voswinckel 2006, ’212 patent D. The ’793 Patent The ’793 patent, titled “Treprostinil …partes review of U.S. Patent No. 10,716,783 (“the ’793 Patent”) in Case No. IPR2021-00406. This… Patent 10,716,793 the Patent Trial and Appeal Board, and a copy External link to document
2023-05-22 10 Pub. L. No. 112–29, 125 Stat. 284 (2011). 3 US 6,521,212 B1, issued Feb. 18, 2003 (Ex. 1006) (alleged to…’066 patent U.S. Patent No. 9,593,066901 patent U.S. Patent No. …’066 patent U.S. Patent No. 9,593,066393 patent U.S. Patent No. …claims of U.S. Patent No. 10,716,793 (the “ʼ793 patent”). On July 19, 2022, the Patent Trial and Appeal…Appellant UTC’s patents were invalid and not infringed—the ’793 patent, and two others: U.S. Patent Nos. 9,604,901 External link to document
2023-05-30 12 Voswinckel JESC, Voswinckel JAHA, and U.S. Patent No. 6,521,212 B1 (Ex. 1006); (…IPR petitions on U.S. Patent No. 9,604,901 (“the ’901 Patent”) and the ’066 Patent on March 30, 2020. The…Because the ’901 Patent IPR began eight months earlier than the ’793 Patent IPR, the ’901 Patent IPR appeal … APPEAL FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE, PATENT TRIAL & APPEAL BOARD, IPR2021… partes review (“IPR”) of U.S. Patent No. 10,716,793 (“the ’793 Patent”) earlier but chose to wait months External link to document
2023-06-02 13 ’s prior art patents and publications, including U.S. Patent Nos. 6,756,033 and 6,521,212, disclosing…prior issued patents, including U.S. Patent Nos. 6,756,033 and 6,521,212, disclosing and claiming methods…s prior art patents and publications, including U.S. Patent Nos. 6,756,033 and 6,521,212, disclosing …prior issued patents, including U.S. Patent Nos. 6,756,033 and 6,521,212, disclosing and claiming methods… art patents and publications, including U.S. Patent Nos. 6,756,033 and 6,521,212, disclosing External link to document
2023-06-09 14 Voswinckel JESC, Voswinckel JAHA, and U.S. Patent No. 6,521,212 B1 (Ex. 1006); (…Pub. L. No. 112–29, 125 Stat. 284 (2011). 3 US 6,521,212 B1, issued Feb. 18, 2003 (Ex. 1006) (alleged to… Voswinckel 2006, ’212 patent D. The ’793 Patent The ’793 patent, titled “Treprostinil …Time for Filing Patent Owner’s Preliminary Response 3/30/2021 Patent Owner’s Updated…Kannappan 5/3/2021 Patent Owner’s Updated Mandatory Notices 5/17/2021 Patent Owner’s Preliminary External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.